Locations:
Search IconSearch

Seeing an Orchard Instead of Trees: A Bold Approach to Healthcare App Development

‘Orchard of Apps’ strategy leverages data elements across neurologic conditions

690×380-Alberts-App

By various measures, last year was a good one for Cleveland Clinic’s C3Logix™ app:

  • Fast-growing numbers of U.S. universities and high schools adopted the app for concussion assessment in their student athletes.
  • Studies validating the app’s ability to precisely quantify postural stability were published and accepted for publication in peer-reviewed journals.
  • Apple even highlighted the app in its popular “What will your verse be?” campaign for the iPad®.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

But the most enduring legacy of C3Logix is likely to be the collection of mobile healthcare apps that Cleveland Clinic’s Neurological Institute has been developing in its wake using selected C3Logix modules and insights from its initial use. These efforts accelerated in 2014 and were formalized into a coordinated strategy — dubbed the “Orchard of Neurological Apps” — to efficiently leverage digital health technology and common data elements across a range of neurologic conditions.

Beyond one-offs

“Instead of using new digital health technologies to create one-off apps, which leads to multiple fragmented approaches to care, we’re looking at mobile apps as modules to be applied across common functional domains for various conditions,” says Cleveland Clinic Concussion Center Director Jay Alberts, PhD, the primary force behind the C3Logix app, which debuted in 2011.

Dr. Alberts took on an additional title in 2014 — Institute Vice Chair for Health Technology Enablement — and was charged with overseeing the Orchard of Neurological Apps strategy.

Leveraging big data

The essence of the strategy is to use related mobile healthcare apps to develop, implement and test predictive treatment models by collecting objective, quantitative outcomes among populations of patients with various neurologic conditions. By building “big data” outcomes repositories through collection of common data elements across these associated apps, the institute aims to guide refinement of care paths and enable predictive models of care.

“Mobile apps provide an unprecedented means to collect objective and truly mineable outcomes throughout the treatment process,” says Dr. Alberts. They also offer singular opportunities for data visualization.

Advertisement

590x-Alberts-App-Inset-1

Figure 1. Example (from the multiple sclerosis app) of the data visualization that’s possible across multiple domains of function under the Neurological Institute’s model of mobile app development.

Shared assessment modules

Central to the strategy is the development of a series of assessment modules that quantify domains of functional impairment common to various neurologic conditions. Dr. Alberts cites the example of postural stability. “Patients with multiple sclerosis, Parkinson disease, stroke or concussion all may have balance problems. So there’s no reason to create separate balance tests for each and have fragmented approaches to assessment.”

Accordingly, the C3Logix app’s balance module has been integrated into Neurological Institute apps for multiple sclerosis, Parkinson disease/essential tremor and fall risk assessment. Similar approaches have been taken with other cognitive and motor domains.

590x-Alberts-App-Inset-2

Figure 2.

Three phases of orchard cultivation

Dr. Alberts foresees the Orchard of Neurological Apps strategy being rolled out in three overlapping phases over the next several years:

  • Phase I involves completing an emerging suite of Neurological Institute care paths with defined goals and care outcomes and integrating them with complementary mobile apps to collect objective outcomes data across the Cleveland Clinic health system. These data (both clinical and patient-reported) will be used to refine care paths and gather foundational data to build predictive care models.
  • Phase II will see deployment of the care paths and mobile apps to affiliate hospitals across the U.S. Such efforts are already underway with the C3Logix app and the multiple sclerosis app. During this phase, tools for real-time predictive analytics will be included within the apps and care paths to promote rapid achievement of patient-specific ideal outcomes.
  • Phase III will consist of identifying the true cost of current patient care scenarios and the cost of delivering care as recommended by the care path. Another goal is to provide the project’s tools for objective assessment, coupled with predictive modeling, to address care delivery gaps in rural and underserved areas.

Advertisement

Toward anticipatory medicine

Operationally, data from the collection of mobile apps will be used to build an ever-evolving database that will allow providers at Cleveland Clinic and beyond to evaluate patients with these apps and identify the clinical state of their patients relative to others presenting with similar symptoms and dysfunction. The provider can then determine how the patient may respond to various interventions (see figure below), the rate of disease progression and other fundamental aspects of management.

“Coordinated application of these tools can move us from an episodic care model to a patient specific model in which clinical decisions are driven by outcomes from large data sets rather than clinical dogma or the treating physician’s experience base,” says Dr. Alberts. “Our aim is to turn mobile devices from expensive electronic notebooks into data collection systems that can transform the quality and cost of medicine.”

590x-Alberts-App-Inset-3

Figure 3. Plots depicting how care may be transformed through predictive analytics for individual patients made possible by the Orchard of Neurological Apps. The top plot represents the current model of care for many neurological patients, with variable outcomes (shown on the y-axis) as different treatments and doses are tried based on response to subjective clinical assessments of cognitive or motor function. The result is time-consuming and costly care that does not optimally serve the patient. The middle plot illustrates the initial value of collecting objective functional outcomes in combination with treatment protocols in a relatively large set of patients (e.g., 1,000). Variability in outcomes over time has been reduced, but the overlap in confidence fields around the plots for Treatments A and B shows some remaining uncertainty about which treatment is best for a patient presenting at a given functional level. The bottom plot shows how clearly distinct outcomes between Treatments A and B might be predicted for a given patient early in management once predictive treatment models are well-populated through large-scale collection (e.g., tens of thousands of patients) of objective outcomes from mobile apps. As the size of the database grows, the predictive modeling has less variability and becomes more patient-specific.

Advertisement

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad